Pacific Biosciences of California Inc (NASDAQ: PACB) Has Another Chance To Impress You
Currently, there are 267.74M common shares owned by the public and among those 259.36M shares have been available to trade. The company’s stock has a 5-day price change of -5.74% and 60.84% over the past three months. PACB shares are trading -76.55% year to date (YTD), with the 12-month market performance down to -65.62% lower. […]
Pacific Biosciences of California Inc (PACB) Testing Investors’ Patience Right Now
Currently, there are 267.74M common shares owned by the public and among those 259.36M shares have been available to trade. The company’s stock has a 5-day price change of 37.85% and 57.93% over the past three months. PACB shares are trading -75.13% year to date (YTD), with the 12-month market performance down to -59.13% lower. […]
Value Hunters: Look To Pacific Biosciences of California Inc (PACB)
Currently, there are 267.74M common shares owned by the public and among those 259.36M shares have been available to trade. The company’s stock has a 5-day price change of 0.00% and -10.24% over the past three months. PACB shares are trading -81.24% year to date (YTD), with the 12-month market performance down to -74.27% lower. […]
Are Analysts Expecting A Better 2020 For Pacific Biosciences of California Inc (PACB)?
Pacific Biosciences of California Inc (PACB) concluded trading on Wednesday at a closing price of $1.75, with 4.09 million shares of worth about $7.16 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 28.68% during that period and on October 23, 2024 the price […]
Reviewing The Case For Pacific Biosciences of California Inc (PACB) Going Higher
Currently, there are 267.74M common shares owned by the public and among those 259.36M shares have been available to trade. The company’s stock has a 5-day price change of 15.12% and 22.22% over the past three months. PACB shares are trading -79.82% year to date (YTD), with the 12-month market performance down to -78.07% lower. […]
Pacific Biosciences of California Inc (NASDAQ: PACB): The Best-Of-Breed For Investing?
Currently, there are 267.74M common shares owned by the public and among those 259.36M shares have been available to trade. The company’s stock has a 5-day price change of 0.00% and 29.77% over the past three months. PACB shares are trading -82.67% year to date (YTD), with the 12-month market performance down to -79.32% lower. […]
Pacific Biosciences of California Inc (PACB) Testing Investors’ Patience Right Now
Currently, there are 267.74M common shares owned by the public and among those 259.95M shares have been available to trade. The company’s stock has a 5-day price change of -6.36% and 26.56% over the past three months. PACB shares are trading -83.49% year to date (YTD), with the 12-month market performance down to -80.60% lower. […]
Stick With Pacific Biosciences of California Inc (PACB). The Bull Are Alive And Well
Currently, there are 267.74M common shares owned by the public and among those 259.95M shares have been available to trade. The company’s stock has a 5-day price change of -5.95% and 20.00% over the past three months. PACB shares are trading -82.26% year to date (YTD), with the 12-month market performance down to -80.67% lower. […]
Growing Through Challenges? – Pacific Biosciences of California Inc (PACB)
Currently, there are 267.44M common shares owned by the public and among those 253.36M shares have been available to trade. Insiders at the company have transacted a total of 19 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 7 of these insider trades were purchases, […]
Pacific Biosciences of California Inc (NASDAQ: PACB) – Suitable For Long Term Buy?
Currently, there are 267.44M common shares owned by the public and among those 256.44M shares have been available to trade. Insiders at the company have transacted a total of 21 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 7 of these insider trades were purchases, […]
